Get the Stockscreener App
0.33
3.79%
-0.013
After Hours:
.33
Turnstone Biologics Corp stock is traded at $0.33, with a volume of 19,033.
It is down -3.79% in the last 24 hours and down -16.24% over the past month.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
See More
Previous Close:
$0.343
Open:
$0.336
24h Volume:
19,033
Relative Volume:
0.10
Market Cap:
$8.72M
Revenue:
$81.89M
Net Income/Loss:
$-55.20M
P/E Ratio:
-0.1224
EPS:
-2.6959
Net Cash Flow:
$-67.40M
1W Performance:
-12.00%
1M Performance:
-16.24%
6M Performance:
-27.55%
1Y Performance:
-87.73%
1-Day Range:
$0.33
$0.3575
1-Week Range:
$0.33
$0.41
52-Week Range:
$0.33
$3.39
Turnstone Biologics Corp Stock (TSBX) Company Profile
Name
Turnstone Biologics Corp
Sector
Industry
Phone
347-897-5988
Address
9310 ATHENA CIRCLE, SUITE 300, LA JOLLA
Compare TSBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSBX
Turnstone Biologics Corp
|
0.33 | 8.72M | 81.89M | -55.20M | -67.40M | -2.6959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Turnstone Biologics Corp Stock (TSBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-15-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-14-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-16-23 | Initiated | SVB Securities | Market Perform |
| Aug-15-23 | Initiated | BofA Securities | Buy |
| Aug-15-23 | Initiated | Piper Sandler | Overweight |
View All
Turnstone Biologics Corp Stock (TSBX) Latest News
Turnstone Biologics stock plunges to 52-week low of $0.33 By Investing.com - Investing.com South Africa
Turnstone Biologics stock plunges to 52-week low of $0.33 - Investing.com
Turnstone Biologics stock plunges to 52-week low of $0.34 By Investing.com - Investing.com South Africa
Turnstone Biologics stock plunges to 52-week low of $0.34 - Investing.com
Q1 EPS Forecast for Turnstone Biologics Decreased by Analyst - Defense World
Analysts Set Expectations for TSBX Q1 Earnings - Defense World
Turnstone Biologics Corp: Strategic Partnerships and Financial Position Justify Hold Rating - TipRanks
Turnstone Biologics Reports 2024 Financial Results - TipRanks
Turnstone Biologics moves to Nasdaq Capital Market By Investing.com - Investing.com South Africa
Turnstone Biologics moves to Nasdaq Capital Market - Investing.com
Turnstone Biologics Corp. SEC 10-K Report - TradingView
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Turnstone Biologics Cuts Losses by $3.6M as Company Pivots Strategy - Stock Titan
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Significant Growth in Short Interest - Defense World
Turnstone Biologics (TSBX) Expected to Announce Earnings on Thursday - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.35 By Investing.com - Investing.com Australia
Turnstone Biologics stock plunges to 52-week low of $0.35 - Investing.com India
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering, Business Wires News - AsiaOne
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Large Drop in Short Interest - Defense World
Turnstone Biologics Stock Hits 52-Week Low at $0.36 Amid Challenges - Investing.com Australia
Turnstone Biologics halts TIDAL-01 development, seeks alternatives - MSN
Turnstone Biologics stock plunges to 52-week low of $0.4 - MSN
Turnstone Biologics stock plunges to 52-week low of $0.4 By Investing.com - Investing.com Canada
Cautious Hold on Turnstone Biologics Amid TIL Therapy Challenges and Strategic Alternatives - TipRanks
Analysts Offer Predictions for TSBX FY2024 Earnings - Defense World
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Leerink Partnrs Weighs in on TSBX FY2024 Earnings - Armenian Reporter
Turnstone Biologics (NASDAQ:TSBX) Stock Rating Lowered by Piper Sandler - Defense World
A Look at Turnstone Biologics Corp (TSBX) Shares in the Recent Past Indicates Growth - SETE News
TSBX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Turnstone Biologics to explore strategic alternatives - The Pharma Letter
Piper Sandler Downgrades Turnstone Biologics to Neutral From Overweight, Adjusts Price Target to $0.40 From $3.75 - Marketscreener.com
Turnstone Biologics Corp (NASDAQ: TSBX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel
Piper Sandler cuts Turnstone Biologics stock rating to neutral - MSN
Turnstone Biologics halts TIDAL-01 development, seeks alternatives By Investing.com - Investing.com South Africa
Ottawa-born Turnstone Biologics halting clinical studies, laying off staff - Ottawa Business Journal
TSBX’s price-to-book ratio: An indicator of the company’s performance - US Post News
Turnstone Biologics Stops Tidal-01 Trials, Explores Strategic Alternatives; Shares Rise - Marketscreener.com
Turnstone Biologics Halts TIDAL-01 Studies Amid Market Woes - TipRanks
Turnstone Biologics Announces Plans to Explore Strategic Alternatives - The Manila Times
Turnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives Review - Nasdaq
Turnstone Biologics Corp Stock (TSBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):